Literature DB >> 18681777

Pharmacogenetics of etanercept in rheumatoid arthritis.

Maria I Danila1, Laura B Hughes, S Louis Bridges.   

Abstract

Etanercept is one of several TNF inhibitors approved for rheumatoid arthritis (RA) and a variety of other immune-mediated inflammatory conditions. Given the plethora of drugs approved for RA, and the wide variations in cost and treatment response, markers of efficacy would be very useful. Several candidate genes, including HLA-DRB1 alleles and those encoding TNF, TNF receptors and Fc receptors, have been examined for a role in the response to treatment with etanercept. In this review, we discuss pharmacogenetic studies of etanercept in RA and other diseases, and comment on the future of such analyses to advance the goal of personalized medicine in RA.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18681777      PMCID： PMC3746504          DOI： 10.2217/14622416.9.8.1011

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


  22 in total

1.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.

Authors:  J M Bathon; R W Martin; R M Fleischmann; J R Tesser; M H Schiff; E C Keystone; M C Genovese; M C Wasko; L W Moreland; A L Weaver; J Markenson; B K Finck
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

Review 2.  Genetic markers of treatment response in rheumatoid arthritis.

Authors:  S Louis Bridges
Journal:  Arthritis Rheum       Date:  2004-04

3.  The response to anti-TNF-alpha treatment: gene regulation at the bedside.

Authors:  N de Vries; P P Tak
Journal:  Rheumatology (Oxford)       Date:  2005-04-26       Impact factor: 7.580

4.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

Review 5.  The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis.

Authors:  P K Gregersen; J Silver; R J Winchester
Journal:  Arthritis Rheum       Date:  1987-11

6.  Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents.

Authors:  Zuhre Tutuncu; Arthur Kavanaugh; Nathan Zvaifler; Maripat Corr; Reena Deutsch; David Boyle
Journal:  Arthritis Rheum       Date:  2005-09

Review 7.  CDP-870 (certolizumab) in rheumatoid arthritis.

Authors:  V V Kaushik; R J Moots
Journal:  Expert Opin Biol Ther       Date:  2005-04       Impact factor: 4.388

8.  The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis.

Authors:  C P Kang; K W Lee; D H Yoo; C Kang; S C Bae
Journal:  Rheumatology (Oxford)       Date:  2005-02-03       Impact factor: 7.580

9.  The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.

Authors:  Lindsey A Criswell; Raymond F Lum; Kevin N Turner; Blanche Woehl; Yuanqing Zhu; Jinyi Wang; Hemant K Tiwari; Jeffrey C Edberg; Robert P Kimberly; Larry W Moreland; Michael F Seldin; S Louis Bridges
Journal:  Arthritis Rheum       Date:  2004-09

10.  Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis.

Authors:  H Schotte; B Schlüter; S Drynda; P Willeke; N Tidow; G Assmann; W Domschke; J Kekow; M Gaubitz
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103
View more
  9 in total

1.  Juvenile idiopathic arthritis: management and therapeutic options.

Authors:  Natasha M Ruth; Murray H Passo
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-04       Impact factor: 5.346

Review 2.  Role of Human Leukocyte Antigens (HLA) in Autoimmune Diseases.

Authors:  Gergely Bodis; Victoria Toth; Andreas Schwarting
Journal:  Rheumatol Ther       Date:  2018-03-07

3.  -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis.

Authors:  Ivan Jančić; Nevena Arsenović-Ranin; Mirjana Sefik-Bukilica; Sladjana Zivojinović; Nemanja Damjanov; Vesna Spasovski; Sanja Srzentić; Biljana Stanković; Sonja Pavlović
Journal:  Rheumatol Int       Date:  2012-12-12       Impact factor: 2.631

Review 4.  Biologics in children's autoimmune disorders: efficacy and safety.

Authors:  Luciana Breda; Marianna Del Torto; Sara De Sanctis; Francesco Chiarelli
Journal:  Eur J Pediatr       Date:  2010-06-17       Impact factor: 3.183

5.  Individualized pain medicine.

Authors:  Hyungsuk Kim; Raymond A Dionne
Journal:  Drug Discov Today Ther Strateg       Date:  2009

Review 6.  Genetics of rheumatoid arthritis - a comprehensive review.

Authors:  Júlia Kurkó; Timea Besenyei; Judit Laki; Tibor T Glant; Katalin Mikecz; Zoltán Szekanecz
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

Review 7.  Pharmacogenetics and pharmacogenomics in rheumatology.

Authors:  Zoltán Szekanecz; Bertalan Meskó; Szilard Poliska; Andrea Váncsa; Szilvia Szamosi; Edit Végh; Enikö Simkovics; Judit Laki; Júlia Kurkó; Timea Besenyei; Katalin Mikecz; Tibor T Glant; László Nagy
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

8.  Influence of Promoter Polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis.

Authors:  Ivan Jančić; Mirjana Šefik-Bukilica; Slađana Živojinović; Nemanja Damjanov; Vesna Spasovski; Nikola Kotur; Kristel Klaassen; Sonja Pavlović; Biljana Bufan; Nevena Arsenović-Ranin
Journal:  J Med Biochem       Date:  2015-09-19       Impact factor: 3.402

Review 9.  Certolizumab in the long-term treatment of rheumatoid arthritis.

Authors:  Abdul Khan; David L Scott
Journal:  Open Access Rheumatol       Date:  2011-08-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.